Riskpilot← Back to searchSign inGet full accessALGIPHARMA AS
ASActiveOrg 964911444Industriveien 33, 1337 SandvikaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 19926 employees
Revenue 2024
NOK 6K
-93% vs 2023
EBITDA margin
-118911.4%
-17% vs 2023
Equity ratio
85.0%
Financial strength
Net profit 2024
NOK -9M
+8% vs 2023
| Revenue | NOK 6K | -93% |
| EBITDA | NOK -6,8M | -17% |
| Net profit | NOK -9M | +8% |
| Total assets | NOK 207,3M | +10% |
| Equity | NOK 176,1M | +37% |
| Employees | 6 | — |
Legal name
ALGIPHARMA AS
Org number
964911444
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25. mai 1992
Share capital
NOK 2 819 601
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap eller tre styremedlemmer i fellesskap.
Company purpose
Forskning og kommersialisering av forskningsprosjekter og forskningsresultater knyttet til alginater og annen bioteknologi og virksomhet i tilknytning til detter, herunder deltakelse i andre virksomheter gjennom aksjeeie eller på annen måte.
Address
Industriveien 33, 1337 Sandvika
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 534 | 110 | 149 | 815 | 3 | 64 | 5 714 | 4 263 | 2 488 | 0 | 65 | 40 | 86 | 6 |
| Staff expenses | −0 | −0 | −798 | −1 500 | −1 906 | −1 336 | −1 582 | −1 834 | −1 643 | −1 969 | −2 200 | −2 705 | −2 561 | −2 237 | −7 743 | −8 649 |
| EBITDA | −54 | −50 | −3 740 | −3 136 | −2 877 | −2 607 | −3 178 | −3 771 | 2 362 | 254 | −13 657 | −8 758 | −6 509 | −7 945 | −5 821 | −6 823 |
| Depreciation & amort. | −0 | −0 | −212 | −192 | −174 | −166 | −2 286 | −158 | −163 | −157 | −150 | −143 | −128 | −0 | −23 | −35 |
| EBIT | −54 | −50 | −3 952 | −3 328 | −3 052 | −2 772 | −5 464 | −3 929 | 2 199 | 97 | −13 807 | −8 902 | −6 637 | −7 945 | −5 844 | −6 858 |
| Net financials | 18 | −144 | −82 | 24 | −915 | −985 | −1 094 | −249 | −1 444 | −2 010 | −2 275 | −3 404 | −4 021 | 872 | −3 988 | −2 104 |
| Profit before tax | −36 | −194 | −4 034 | −3 304 | −3 967 | −3 758 | −6 559 | −4 178 | 754 | −1 913 | −16 082 | −12 306 | −10 658 | −7 073 | −9 832 | −8 963 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −116 | −0 |
| Net profit | −36 | −194 | −4 034 | −3 304 | −3 967 | −3 758 | −6 559 | −4 178 | 754 | −1 913 | −16 082 | −12 306 | −10 658 | −7 073 | −9 716 | −8 963 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 21 790 | 35 687 | 31 130 | 43 235 | 59 528 | 77 897 | 90 432 | 83 728 | 114 288 | 117 579 | 144 606 | 144 458 | 155 526 | 173 351 | 188 879 | 207 326 |
| Equity | 18 790 | 25 096 | −984 | 10 712 | 6 745 | 57 987 | 48 370 | 44 191 | 69 946 | 68 032 | 57 925 | 45 619 | 34 962 | 27 888 | 128 588 | 176 145 |
| Long-term debt | 0 | 0 | 23 092 | 26 732 | 46 838 | 15 330 | 33 331 | 29 481 | 27 867 | 29 859 | 69 089 | 89 336 | 112 260 | 127 767 | 47 666 | 14 824 |
| Short-term debt | 3 000 | 10 592 | 9 022 | 5 791 | 5 945 | 4 580 | 8 732 | 10 056 | 16 475 | 19 688 | 17 592 | 9 503 | 8 305 | 17 695 | 12 625 | 16 356 |
| Total debt | 3 000 | 10 592 | 32 114 | 32 523 | 52 783 | 19 910 | 42 062 | 39 536 | 44 342 | 49 547 | 86 681 | 98 839 | 120 565 | 145 463 | 60 291 | 31 180 |
EBITDA margin
-118911.4%
This company
15.8%
Market median
-752704% vs market
20082024
Equity ratio
85.0%
This company
38.2%
Market median
+123% vs market
20082024
Return on equity
-5.1%
This company
18.4%
Market median
-128% vs market
20082024
Net profit margin
-156195.6%
This company
8.1%
Market median
-1928441% vs market
20082024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
YP Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Algipharma Holding As | Company | 100.0% | 100.0% | 2024 |
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Frydenberg As
ALGIPHARMA AS Board members of ALGIPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yngvar Peter Berg | Chief Executive Officer | 0 companies |
| Diderik Børsting Schnitler | Board of Directors | 0 companies |
| Arne Dessen | Chairman | 0 companies |